<DOC>
	<DOCNO>NCT00792662</DOCNO>
	<brief_summary>The primary purpose study determine study medication Methylphenidate ( Ritalin ) improve subject 's blood-sugar control improve motivation placebo . The secondary objective study determine daily function quality life improve methylphenidate treatment .</brief_summary>
	<brief_title>Improving Function , Quality Life , Glycemia Diabetics With Dementia</brief_title>
	<detailed_description>A total 50 subject enrol study . This study conduct two site , UNMC Omaha VA Medical Center . The subject ask take study drug form capsule take twice daily . Whether subject receives methylphenidate placebo ( pill similar appearance study drug , medicine ) determine random chance . The probability subject receive methylphenidate 1 every 2 subject 50 % time . Subjects receive methylphenidate start 5 milligram ( mg ) twice daily . Dosage increase 10mg twice daily 2 week . After initial visit , subject ask come follow-up every month next 4 visit ( sixteen week total ) . During visit subject ask question assess motivation , memory , functional status quality life . Blood drawn electrocardiogram ( ecg/ekg ) take assess patient 's safety twice study . Partial Compensation may available participation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Diagnosis dementia Alzheimer type ( Diagnostic Statistical ManualIV Text Revision ( DSMIV TR ) criterion ) 2 . Diagnoses diabetes mellitus type II 3 . Poor glycemic control ( Hemoglobin A1c ( HbA1c ≥ 7.0 % ) ) 4 . Mild Moderate Alzheimer 's dementia ( Mini Mental State Examination ( MMSE ) &gt; 18 , &lt; 29 ) 5 . Apathy Evaluation Scale ( AES ) score 30 6 . Ability provide inform consent either patient caregiver . 7 . If subject treat antidepressant , stable dose antidepressant least two month prior enrollment study . 8 . If subject treat cholinesterase inhibitor memantine , stable dose medication least four month prior enrollment study . 9 . Subjects stable dose statin ACE inhibitor ≥ 2 month . 10 . Subjects stable dose diabetes treatment 2 month prior enrollment . 1 . Severe dementia ( MMSE &lt; 18 ) 2 . Patient currently take methylphenidate hypersensitivity prior significant adverse event methylphenidate . 3 . Patients currently take Adderall ( amphetamine mixed salt ) Dexedrine ( dextroamphetamine sulphate ) amphetamine product . 4 . Uncontrolled hypertension ( BP &gt; 140/90 ) tachycardia ( 100 ) screen visit 5 . Patients frontotemporal dementia 6 . Patients meet criterion Major Depressive Disorder Mini International Neuropsychiatric Inventory ( MINI ) 7 . Patients active psychosis determine MINI 8 . Patients currently treat antipsychotic 9 . History uncontrolled seizure disorder 10 . History malignant hypertension , symptomatic cardiovascular disease , cardiomyopathy , known structural cardiac defect medically unstable arrhythmia . 11 . History Tourette 's syndrome presence motor tic 12 . Patients glaucoma 13 . Patients take monoamine oxidase inhibitor ( MAOIs ) 14 . Patient take clonidine 15 . Patients treat insulin pump</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Apathy</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Dementia</keyword>
</DOC>